07 Oct 2026, 15:25 IST
Dr. Reddy's Laboratories Limited
HDFC Securities · REDUCE · target Rs 1,200
The report expects a 4% YoY revenue decline and a sharp EBITDA margin contraction due to absence of gRevlimid and price erosion, flagging it as a muted performer.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.